QNRX vs. VVOS, PETV, RVP, NXGL, ALUR, CLGN, NRXS, PSTV, NXL, and IRIX
Should you be buying Quoin Pharmaceuticals stock or one of its competitors? The main competitors of Quoin Pharmaceuticals include Vivos Therapeutics (VVOS), PetVivo (PETV), Retractable Technologies (RVP), NexGel (NXGL), Allurion Technologies (ALUR), CollPlant Biotechnologies (CLGN), NeurAxis (NRXS), Plus Therapeutics (PSTV), Nexalin Technology (NXL), and IRIDEX (IRIX). These companies are all part of the "medical equipment" industry.
Quoin Pharmaceuticals vs. Its Competitors
Quoin Pharmaceuticals (NASDAQ:QNRX) and Vivos Therapeutics (NASDAQ:VVOS) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their valuation, media sentiment, profitability, analyst recommendations, institutional ownership, earnings, dividends and risk.
Quoin Pharmaceuticals has higher earnings, but lower revenue than Vivos Therapeutics. Vivos Therapeutics is trading at a lower price-to-earnings ratio than Quoin Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Vivos Therapeutics has a consensus target price of $4.82, suggesting a potential upside of 13.87%. Given Vivos Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Vivos Therapeutics is more favorable than Quoin Pharmaceuticals.
Quoin Pharmaceuticals has a beta of 1.47, indicating that its share price is 47% more volatile than the S&P 500. Comparatively, Vivos Therapeutics has a beta of 7.01, indicating that its share price is 601% more volatile than the S&P 500.
8.6% of Quoin Pharmaceuticals shares are held by institutional investors. Comparatively, 26.4% of Vivos Therapeutics shares are held by institutional investors. 3.7% of Quoin Pharmaceuticals shares are held by insiders. Comparatively, 3.0% of Vivos Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
In the previous week, Vivos Therapeutics had 4 more articles in the media than Quoin Pharmaceuticals. MarketBeat recorded 5 mentions for Vivos Therapeutics and 1 mentions for Quoin Pharmaceuticals. Vivos Therapeutics' average media sentiment score of 0.88 beat Quoin Pharmaceuticals' score of 0.00 indicating that Vivos Therapeutics is being referred to more favorably in the news media.
Quoin Pharmaceuticals has a net margin of 0.00% compared to Vivos Therapeutics' net margin of -76.82%. Quoin Pharmaceuticals' return on equity of -148.97% beat Vivos Therapeutics' return on equity.
Summary
Vivos Therapeutics beats Quoin Pharmaceuticals on 9 of the 15 factors compared between the two stocks.
Get Quoin Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for QNRX and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding QNRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Quoin Pharmaceuticals Competitors List
Related Companies and Tools
This page (NASDAQ:QNRX) was last updated on 7/5/2025 by MarketBeat.com Staff
Free QNRX Stock Alerts